Navigation Links
Publication of Supplementary Prospectus
Date:4/29/2008

h the Proposals and will not be responsible to anyone other than Shire and Shire Limited for the protections afforded to its clients or for providing advice in relation to the Proposals or the content of this announcement.

This announcement does not constitute an invitation or offer to sell or the solicitation of an invitation or offer to buy any security. none of the securities referred to in this announcement shall be sold, issued, exchanged or transferred in any jurisdiction in contravention of applicable laws.

Notice to United States Residents

This announcement is not an offer of securities in the United States.

The Shire Limited ordinary shares to be issued in connection with the proposals will not be, and are not required to be, registered with the US Securities and Exchange Commission under the US Securities Act of 1933, as amended, in reliance on the exemption from registration provided by Section 3(a)(10) thereof.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGF(beta)3) and veleglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, including but not limited to,
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells
2. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
3. United BioSource Acquires Leading Publication Planning Software and Services Company
4. Publication Addresses Misconceptions About Emergency Contraception
5. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
6. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
7. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
8. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
9. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
10. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
11. Research by Case Western Reserve University, VA earns cover of prestigious science publication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 23, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... first quarter 2015 results before the Nasdaq market opens ... a live conference call and webcast to discuss its financial ... 30, 2015 at 8:00 a.m. Eastern Time (5:00 a.m. ... conference call by dialing 866-952-1906 (US) or 785-424-1825 (International) ...
(Date:4/23/2015)... Calif. , April 23, 2015  Veracyte, Inc. (NASDAQ: ... into a definitive agreement to sell approximately $40 million ... the agreement, the investors will purchase an aggregate of ... of $8.15 per share, the closing stock price on ... new and existing investors, including Broadfin Capital, Camber Capital, ...
(Date:4/23/2015)...  Metanome, Inc., an industry leader in comprehensive ... its name to Diversigen, Inc.  The name was ... commercial source for the myriad of services and ... opportunities of the microbiome.  From the wide diversity ... those that are difficult to handle, such as ...
(Date:4/23/2015)... April 23, 2015 Delpor, Inc. (Delpor), ... that the United States Patent and Trademark Office has ... NANOPORâ„¢ technology. US Pat. No. 8,986,727 was ... drug delivery device for the sustained release ... technology for the sustained (zero-order) release of large and ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... with minimal patient discomfort, SPOKANE, Wash., Nov. ... launch of the ComforTen(TM) Multiple Skin,Test System, its ... steel 1.2mm lancet tips, which create minimal skin ... 10-test, self-loading,surgical steel testing device on the market. ...
... NEW YORK, Nov. 9 Lev Pharmaceuticals, Inc.,(OTC Bulletin Board: LEVP.OB) today announced ... 13, 2007, at 1:00,p.m. Eastern Time (ET), in conjunction with the release of ... financial results at 7:00 a.m. ET on Tuesday, November 13,2007. DATE: ... 2007 TIME: ...
... Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), a ... product candidates principally,for use in the hospital setting, ... ended September 30, 2007 financial results after the ... Cadence management will host a conference call and ...
Cached Biology Technology:HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 2HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 3Lev Pharmaceuticals Invites You to Participate in its Q3'07 Earnings Results Conference Call and Webcast 2Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results 2
(Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... January 21, JoVE, the Journal of Visualized Experiments ... that explored one of the most intriguing research questions ... The protocol, titled Conducting Miller-Urey Experiments, is comprised of ... by Dr. Stanley Miller and Dr. Harold Urey in ...
... in the early stages of multiple sclerosis (MS), low levels ... and hasten its progression, according to a new study led ... with Bayer HealthCare. The findings suggest that patients in the ... increasing their vitamin D intake. "Because low vitamin D ...
... longs fora master key that allows them to escape. A study ... how a protein that promotes tumor growth also enables cancer cells ... a blood or lymphatic vessel, a cancer cell is imprisoned in ... tumor cell,s master key. It loosens connections between endothelial cells that ...
Cached Biology News:A 21st century adaptation of the Miller-Urey origin of life experiments 2Boosting vitamin D could slow progression, reduce severity of multiple sclerosis 2FAK helps tumor cells enter the bloodstream 2
... and Non-ionic Detergent Removal , ... selective, virtually no cross-reactivity with other proteins ... pellet , Economical new surface technology, ... can often interfere with protein analysis. SurfactAway ...
Physical Form: saline suspension with ethanol Particle Dim: mean particle size 50 μm Matrix: HyperD F. Useful for the removal of detergents from protein samples....
... workstation automates a wide array of research ... Sample Preparation to Bio-Molecular and Cell Based ... the Caliper Sciclone enables numerous combinations of ... the needs of a given application, and ...
General description: MaxiSorp TM surface is ideal for arraying molecules with mixed hydrophilic/hydrophobic domains such as proteins ID clarifier: Maxisorp(tm) with lid...
Biology Products: